ライフサイエンスコーパス: duration of treatment

1 ment should be considered in determining the duration of treatment.

2 which bisphosphonates should be used and the duration of treatment.

3 dose-dependent but was less with increasing duration of treatment.

4 n deprivation therapy and is correlated with duration of treatment.

5 d youth do not receive adequate follow-up or duration of treatment.

6 and particularly those that can shorten the duration of treatment.

7 ps determine the patient's prognosis and the duration of treatment.

8 and assists in establishing the appropriate duration of treatment.

9 Greater protection was noted with longer duration of treatment.

10 an effect that directly correlated with the duration of treatment.

11 cally depending on the concentration and the duration of treatment.

12 ereas dyskinesias could be best predicted by duration of treatment.

13 ivided into years of follow-up or increasing duration of treatment.

14 significantly delayed worm expulsion for the duration of treatment.

15 immediate relapse and higher cost and longer duration of treatment.

16 he intensity of tolerance increases with the duration of treatment.

17 e stage at which embryos were treated or the duration of treatment.

18 equirements for amino acid concentration and duration of treatment.

19 troma correlate with the cumulative dose and duration of treatment.

20 establishing a standard recommendation about duration of treatment.

21 n males and possibly in patients with longer duration of treatment.

22 , rendering their eruption tolerable for the duration of treatment.

23 material and with a limited and controllable duration of treatment.

24 the effect depending on the dose of GSPE and duration of treatment.

25 are assessed at diagnosis and throughout the duration of treatment.

26 d, how much steroid to give, and the optimum duration of treatment.

27 ay improve overall survival (OS) with longer duration of treatment.

28 t-limiting side effects and a long (48-week) duration of treatment.

29 evel of quantitation (<25 IU/mL) through the duration of treatment.

30 r or no prior use of immunosuppressants, and duration of treatment (1 to 24 months vs. 25 to 48 month

31 ome other effects, possibly due to the short duration of treatment (10 months).

32 her was slightly more frequent with a longer duration of treatment: 12 (2.9%) of 416 patients assigne

33 were divided into three groups according to duration of treatment: 24 (N = 14), 48 (N = 82), or 72 (

34 no difference between groups in the average duration of treatment (27.5 [SD 21.5], 24.9 [17.7], 27.9

35 RECENT FINDINGS: Extended duration of treatment (36 months) with adjuvant imatinib

36 otently inhibits S6K activity throughout the duration of treatment, 4E-BP1 recovers in phosphorylatio

37 d or greater severity increased according to duration of treatment: 90 to 180 days, 1.5 (P=0.23); 181

38 moxifloxacin for isoniazid permits a shorter duration of treatment, a second study was performed in w

39 The duration of treatment after achieving a satisfactory res

40 of pretreatment before stenting, the optimal duration of treatment after drug-eluting stent implantat

41 allocated treatment and received treatment, duration of treatment and cause of discontinuation, main

42 t of SBS, optimal patient selection for use, duration of treatment and cost effectiveness require fur

43 essed by 2 reviewers, study definitions, and duration of treatment and follow-up.

44 t status, number of treatment interruptions, duration of treatment and interruption, changes in viral

45 Median duration of treatment and mean daily dose were 12.5 mont

46 ed the association of race and survival with duration of treatment and number of treatment cycles amo

47 vement in PROs that continued throughout the duration of treatment and post-treatment.

48 blingual buprenorphine resulted in a shorter duration of treatment and shorter length of hospital sta

49 If the association we observed between duration of treatment and survival is confirmed, additio

50 aluate the potential association between the duration of treatment and the prevalence of heart valve

51 The optimal duration of treatment and utility of follow-up blood cul

52 Benefit increased with duration of treatment and was consistent across the diff

53 iated with GGTI treatment in vivo limits the duration of treatment and, thus, may limit the therapeut

54 ndent vasodilation in direct relationship to duration of treatments and reduced wall thickness in as

55 ient quality of life, can limit the dose and duration of treatment, and may be life-threatening, spec

56 dence of postpartum affective disorder (AD), duration of treatment, and rate of subsequent postpartum

57 outcome measures were risk of postpartum AD, duration of treatment, and recurrence risk.

58 ue to colorectal cancer in relation to dose, duration of treatment, and site of tumour.

59 tly needed for resistant strains, shortening duration of treatment, and targeting different stages of

60 (CEL), little is known about optimal dosing, duration of treatment, and the possibility of cure in th

61 nduction versus maintenance treatment, total duration of treatment, and the utility of therapeutic mo

62 mutations with disease, duration of illness, duration of treatment, and total therapeutic dose of aza

63 initiation of PMPA treatment as well as the duration of treatment are crucial factors for prevention

64 Issues concerning the timing and duration of treatment are discussed.

65 The optimum frequency and duration of treatment are unknown.

66 inimum effective dose and shortest necessary duration of treatment as well as the mechanism of antide

67 of careful risk-benefit review of dosage and duration of treatment as well as their off-label use.

68 Duration of treatment averaged 10.5 +/- 2.6 d.

69 ndent of the underlying risk of relapse, the duration of treatment before randomisation, or the durat

70 trials are required to determine the optimal duration of treatment before widespread use is advocated

71 in the number of treatment sessions and the duration of treatment, CBT was more effective in relievi

72 e patients treated with nesiritide, the mean duration of treatment changed minimally, from 2.3 to 2.1

73 and frequency of drug administration, median duration of treatment, clearance and recurrence rates, a

74 tive, are hampered by high pill burden, long duration of treatment, coexistent toxic effects, and an

75 Longer duration of treatment conferred greater fracture risk.

76 In addition to the duration of treatment, core promoter mutation was associ

77 P = 0.001), whereas the cumulative dose and duration of treatment correlate significantly with the d

78 Duration of treatment correlated positively with volumes

79 Duration of treatment, cumulative dose, Orlando stage (s

80 As expected, HDV inhibition exhibited duration-of-treatment dependence.

81 Duration of treatment did not affect relapse in patients

82 conducted on combination antibiotic therapy, duration of treatment, dosing of aminoglycosides, altern

83 cells depend on the viral load, timing, and duration of treatment during the course of the infection

84 The secondary efficacy end point was the duration of treatment effect measured as time from the i

85 reatment (QALYs = [gain in utility value] x [duration of treatment effect]).

86 but were limited in evaluating the scope and duration of treatment effects.

87 Mean duration of treatment efficacy was 127 days (SD 37) with

88 received ZD9331 daily for 2 weeks, with the duration of treatment escalated to a maximum of 4 weeks,

89 djusted HR, 1.08 [95% CI, 0.59-1.91]) unless duration of treatment exceeded 10 years (6 cases among 3

90 Patient age, previous drug therapy, duration of treatment, flecainide levels and corrected Q

91 e addressed the quality of follow-up care or duration of treatment for depressed youth.

92 esized that clofazimine may also shorten the duration of treatment for drug-susceptible TB.

93 The duration of treatment for established anthrax is controv

94 The optimal dose, time to start, and duration of treatment for many appetite stimulants for c

95 ptimal route of administration, and dose and duration of treatment for mitomycin C.

96 The primary end point was the duration of treatment for symptoms of neonatal opioid wi

97 Personalization of the duration of treatment for TB, especially for patients wi

98 The median duration of treatment for the 204 patients was 5.7 month

99 , P<0.0091), and had a significantly shorter duration of treatment for the neonatal abstinence syndro

100 The mean (SD) durations of treatment for the operative and endovascula

101 tion of PMPA treatment, as well as different durations of treatment, for the ability to prevent estab

102 Increasing the duration of treatment from 1 week to 3 weeks resulted in

103 irin allows for the potential to shorten the duration of treatment from 24 to 12-14 weeks without red

104 We varied ligand (dose, chemistry, and duration of treatment), GR (expression level and functio

105 Duration of treatment > 2 years; suppuration and dental

106 nin reuptake inhibitors and who had a longer duration of treatment had significantly lower risks of m

107 Although the optimal duration of treatment has not been determined, more prol

108 concerns over the antibiotics chosen and the duration of treatment have been raised.

109 nt difference in response rates based on the duration of treatment; HCV genotype was the strongest pr

110 efficacy, with potential for shortening the duration of treatment in a majority of patients.

111 uals infected with HCV, as well as a shorter duration of treatment in many individuals.

112 determine the optimal timing, schedule, and duration of treatment in men with bone metastases as wel

113 The mean omega-3 PUFAs dose and duration of treatment in the new trials was 2.4 g/day an

114 rferon alpha-2b and ribavirin dosage for the duration of treatment in the setting of a clinical trial

115 We assessed the impact of PDE-Is on the duration of treatment in tuberculous mice.

116 ource of bias -- mismeasurement of patients' duration of treatment -- in previous research on pharmac

117 Median duration of treatment incorporating overnight wear was 8

118 At data cutoff, median duration of treatment (induction) was 8.9 weeks (IQR 4.1

119 oth the dietary methyl donor content and the duration of treatment influenced methylation and express

120 nadotropic hypogonadism after a mean (+/-SD) duration of treatment interruption of 6+/-3 weeks.

121 The risk of chronic GVHD is higher and the duration of treatment is longer after HCT with mobilized

122 or outcome, optimal therapeutic regimens and duration of treatment is much needed.

123 less-in terms of the number of drugs and the duration of treatment-is better.

124 stopped relatively early, and that a longer duration of treatment leads to failure.

125 more of lactic acid bacteria per day for the duration of treatment (median 33 days).

126 iation had a significantly (P < .01) shorter duration of treatment (median, 62.5 days) compared with

127 rug trials as they relate to sample size and duration of treatment necessary to detect an effect from

128 18% of users reached the minimally required duration of treatment of 3 years (SCIT, 23%; SLIT, 7%).

129 days on/10 days off) prednisolone for a mean duration of treatment of 4 years.

130 The duration of treatment of gastrointestinal tuberculosis c

131 olymerase chain reaction (QPCR) to determine duration of treatment of transplant patients with human

132 The optimal duration of treatment of women with postmenopausal osteo

133 s the importance of agonist efficacy and the duration of treatment on the neuroprotective effects of

134 but whether this results from the increased duration of treatment or a higher cumulative dose remain

135 only), and ability to tolerate full dose and duration of treatment (P < .0001) were predictors of SVR

136 s related to both total dose (P < 0.001) and duration of treatment (P < 0.001).

137 Duration of treatment, participants receiving dose-spari

138 he degree of suppression correlated with the duration of treatment; patients treated for <1 month had

139 have assessed the appropriate frequency and duration of treatment programs.

140 dose (range across trials: 3.0-12.4 g/d) or duration of treatment (range: 2-12 wk) influenced the re

141 Average duration of treatment ranged from 6 months to 34 months,

142 The duration of treatment ranged from week-long follow up fo

143 from 24 to 48 or 72 h p.i. or decreasing the duration of treatment reduced effectiveness in preventin

144 of selection of patients, drug regimen, and duration of treatment remain unresolved.

145 direct-acting antiviral drug can reduce the duration of treatment required to achieve sustained vira

146 Median duration of treatment response (using the time to progre

147 However, tumor eradication is rare, and duration of treatment response is limited by the develop

148 nts who received the drug, regardless of the duration of treatment, revealed 14 partial responses (PR

149 Duration of treatment should be further optimized based

150 Technical success, duration of treatment, stroke, return to the operating r

151 curring course of insomnia, both the limited duration of treatments studied and the lack of follow-up

152 However, benefit increased with scheduled duration of treatment, such that allocation to aspirin o

153 Depending on dose and duration of treatment, survival ranged from 57.1% to 80.

154 igible patients with a significantly shorter duration of treatment than with standard-fractionation c

155 irin in the regimen or with extension of the duration of treatment to 12 weeks.

156 or application (time on/time off), and total duration of treatment to attain desired clinical outcome

157 erapy and irradiation on treatment toxicity, duration of treatment, tumor recurrence, and survival we

158 The median duration of treatment was 13.8 months.

159 202 ICU patients with bacteremia, the median duration of treatment was 14 days, but with wide variabi

160 The median duration of treatment was 14 months.

161 The median (range) duration of treatment was 15 (7-34) months; the frequenc

162 2)] and 40% treated with identical placebo); duration of treatment was 18 months.

163 Duration of treatment was 18 months.

164 The mean duration of treatment was 21 +/- 7 months.

165 The median duration of treatment was 21 months.

166 re recurrent malignancy or death, the median duration of treatment was 23 months.

167 Median duration of treatment was 291 days (IQR 239-354).

168 Duration of treatment was 3 months, followed by repeat e

169 The mean (+/-SD) duration of treatment was 3.5+/-0.9 years in the LHRH-ag

170 e dose was initially 2 mg/kg per day and the duration of treatment was 32 days.

171 The median duration of treatment was 364 days in the risperidone gr

172 mean dosage of aspirin was 273 mg/d and mean duration of treatment was 37 months.

173 Duration of treatment was 4 years.

174 Mean duration of treatment was 4.3 years.

175 Median follow-up was 16.8 months; median duration of treatment was 4.9 months.

176 The mean duration of treatment was 5.4 years.

177 Median duration of treatment was 7.1 months (range 0.7-34.4, IQ

178 The average duration of treatment was 71 to 72 days in each of the t

179 The average duration of treatment was 73 days.

180 Median duration of treatment was 9 weeks (IQR 8-14 weeks).

181 Duration of treatment was a median of 90 min (range 25-3

182 the 2 treatment groups was similar when the duration of treatment was considered.

183 Once the maximum-tolerated duration of treatment was determined, the dose of ZD9331

184 Duration of treatment was event-driven and the trial las

185 For each medication, the duration of treatment was most often limited by factors

186 Type or duration of treatment was not associated with a second U

187 The median duration of treatment was significantly shorter with bup

188 The dose of G-CSF and duration of treatment were correlated with the extent of

189 ian peak viral load, duration of viremia and duration of treatment were highest during primary infect

190 Duration of treatment, which was 20 +/- 2.1 mo in 1980,

191 ould be started and choice of medication and duration of treatment will maximize the benefits of frac

192 The mean duration of treatment with 3% saline was 7.6 days (range

193 Partial responses were observed, but the duration of treatment with AUY922 and erlotinib was limi

194 Median duration of treatment with bevacizumab was 51 weeks (IQR

195 y homogenate of CsA-treated rats relative to duration of treatment with CsA (r2 = 0.486, P < 0.001).

196 hown to significantly accumulate relative to duration of treatment with CsA when immunoreactive bands

197 Shortening the duration of treatment with HCV direct-acting antivirals

198 therapy in some patients, resulting in long duration of treatment with higher doses (>40 mg AD), may

199 luded the duration of untreated disease, the duration of treatment with immunosuppressive medications

200 accelerate drug development and minimize the duration of treatment with ineffective regimens in cance

201 However, the ideal duration of treatment with interferon-free regimens, par

202 An 8-week duration of treatment with LDV/SOF is highly effective i

203 The average duration of treatment with masked trial medication was 1

204 More women engaged in a sufficient duration of treatment with medications compared with psy

205 Median duration of treatment with methotrexate was 21.5 months

206 focal leukoencephalopathy increases with the duration of treatment with natalizumab.

207 italization, number of days in the hospital, duration of treatment with parenteral antibiotics, or nu

208 The duration of treatment with prednisolone at >40 mg on alt

209 Median duration of treatment with T-VEC was 13.3 weeks (range,

210 dose of aromatase-inhibitor therapy, and the duration of treatment with tamoxifen).

211 The duration of treatment with thalidomide was too short to

212 The mean +/- SD duration of treatment with the identified atypical antip

213 the onset of inactive disease, or the total duration of treatment with TNFalpha antagonists prior to

214 describe the number of follow-up visits and duration of treatment within 6 months of first prescript

215 ed to recruit 2200 patients, and the minimum duration of treatment would be 6 months.

216 A shorter duration of treatment wth pegylated interferon and ribav